Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis

Carcinogenesis

Volumn 32, Issue 4, 2011, Pages 477-487

  Mi, Zhiyong ^b   Bhattacharya, Syamal D ^a   Kim, Victoria M ^a   Guo, Hongtao ^b   Talbotq, Lindsay J ^a   Kuo, Paul C ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALVASCULIN; CELL SURFACE RECEPTOR; GELATINASE A; GELATINASE B; HOMODIMER; INTEGRIN; OSTEOPONTIN; PROTEIN C JUN; RANTES; STROMAL CELL DERIVED FACTOR 1; TENASCIN; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CELL TRANSFORMATION; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LIVER METASTASIS; LUNG METASTASIS; MALIGNANT TRANSFORMATION; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; STROMA CELL; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOKINE CCL5; COCULTURE TECHNIQUES; FEMALE; HUMANS; MESENCHYMAL STEM CELLS; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OSTEOPONTIN; STROMAL CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 79953727008     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr009     Document Type: Article

References (30)

1. Karnoub, A.E. et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449, 557-563.
2. Pinilla, S. et al. (2009) Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett., 284, 80-85.
3. Denhardt, D.T. et al. (1995) Osteopontin-induced modifications of cellular functions. Ann. N. Y. Acad. Sci., 760, 127-142.
4. Denhardt, D.T. et al. (2001) Role of osteopontin in cellular signaling and toxicant injury. Annu. Rev. Pharmacol. Toxicol., 41, 723-749.
5. Weber, G.F. et al. (1997) Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc. Assoc. Am. Physicians, 109, 1-9.
6. Denhardt, D.T. et al. (1994) Overcoming obstacles to metastasis-defenses against host defences: osteopontin as a chield against attack by sytotoxic host cells. J. Cell. Biochem., 56, 48-51.
7. Brown, L.F. et al. (1994) Osteopontin expression and distribution in human carcinomas. Am. J. Pathol., 145, 610-623.
8. Agrawal, D. et al. (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl Cancer Inst., 94, 513-521.
9. Coppola, D. et al. (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res., 10, 184-190.
10. Das, R. et al. (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem., 278, 28593-28606.
11. Fedarko, N.S. et al. (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res., 7, 4060-4066.
12. Gotoh, M. et al. (2002) Overexpression of osteopontin in hepatocellular carcinoma. Pathol. Int., 52, 19-24.
13. Grano, M. et al. (2002) HGF and M-CSF modulate adhesion of MDA-231 breast cancer cell by increasing osteopontin secretion. J. Biol. Regul. Homeost. Agents, 16, 190-195.
14. Wai, P.Y. et al. (2004) The role of Osteopontin in tumor metastasis. J. Surg. Res., 121, 228-241.
15. McAllister, S.S. et al. (2008) Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell, 133, 994-1005.
16. Bramwell, V.H. et al. (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin. Cancer Res., 12, 3337-3343.
17. Mi, Z. et al. (2009) RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol. Ther., 17, 153-161.
18. Keng, P.C. et al. (1990) Evaluation of cell subpopulations isolated from human tumor xenografts by centrifugal elutriation. Int. J. Radiat. Oncol. Biol. Phys., 18, 1061-1067.
19. Wai, P.Y. et al. (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev., 27, 103-118.
20. Nelson, P.J. et al. (1993) Genomic organization and transcriptional regulation of the RANTES chemokine gene. J. Immunol., 151, 2601-2612.
21. Shimoda, M. et al. (2009) Carcinoma-associated fibroblasts are a ratelimiting determinant for tumour progression. Semin. Cell Dev. Biol., 21, 19-25.
22. Ostman, A. et al. (2009) Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev., 19, 67-73.
23. Mishra, P.J. et al. (2008) Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res., 68, 4331-4339.
24. Muehlberg, F.L. et al. (2009) Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis, 30, 589-597.
25. Orimo, A. et al. (2001) Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin. Cancer Res., 7, 3097-3105.
26. Spaeth, E.L. et al. (2009) Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One, 4, e4992.
27. Azenshtein, E. et al. (2002) The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res., 62, 1093-1102.
28. Finak, G. et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med., 14, 518-527.
29. Udagawa, T. et al. (2006) Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J., 20, 95-102.
30. Wang, H. et al. (2009) Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells, 27, 1548-1558.